{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:39:40Z","timestamp":1792075180871,"version":"4.4.0"},"reference-count":61,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,6,19]]},"DOI":"10.18632\/oncotarget.28458","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T12:33:51Z","timestamp":1687178031000},"page":"622-636","source":"Crossref","is-referenced-by-count":10,"title":["Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer"],"prefix":"10.18632","volume":"14","author":[{"given":"Devalingam","family":"Mahalingam","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"},{"name":"Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Hanni","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"Serritella","sequence":"additional","affiliation":[{"name":"Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Fountzilas","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"},{"name":"Roswell Park Cancer Institute, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Michalek","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[{"name":"Institute for Drug Development, Mays Cancer Center at University of Texas Health, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paromitta","family":"Datta","sequence":"additional","affiliation":[{"name":"Audie Murphy VA Hospital, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofelia","family":"Romero","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sureshkumar Mulampurath Achutan","family":"Pillai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pollak","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine, Lady Davis Institute of Medical Research, Jewish General Hospital, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX 77030, USA"},{"name":"Christus Health, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"7","author":"Jemal","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/1756287217697661","article-title":"Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence","volume":"9","author":"Peltier","year":"2017","journal-title":"Ther Adv Urol"},{"key":"3","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"34","author":"Trump","year":"1999","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"2","author":"Wade","year":"2007","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","article-title":"Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer","volume":"6","author":"Suissa","year":"2011","journal-title":"Eur Urol"},{"key":"6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/jdi.12472","article-title":"Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis","volume":"7","author":"Zhao","year":"2016","journal-title":"J Diabetes Investig"},{"key":"7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2013.02.023","article-title":"Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer","volume":"6","author":"Smith","year":"2014","journal-title":"Eur Urol"},{"key":"8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.18553\/jmcp.2003.9.s1.2","article-title":"The National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"9","author":"Lipsy","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"9","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"28","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/annonc\/mdr037","article-title":"Metformin in prostate cancer: two for the price of one","volume":"2","author":"Gurney","year":"2011","journal-title":"Ann Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c110062","article-title":"Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training","volume":"3","author":"Barnard","year":"2013","journal-title":"Compr Physiol"},{"key":"12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1472-6823-11-18","article-title":"Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)","volume":"1","author":"Miner","year":"2011","journal-title":"BMC Endocr Disord"},{"key":"13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.maturitas.2012.10.016","article-title":"Total testosterone and sex hormone-binding globulin are associated with metabolic syndrome independent of age and body mass index in Korean men","volume":"7","author":"Kim","year":"2013","journal-title":"Maturitas"},{"key":"14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/COC.0b013e318201a406","article-title":"Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review","volume":"3","author":"Hollins","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"11","author":"Litwin","year":"2007","journal-title":"Cancer"},{"key":"16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1634\/theoncologist.2010-0338","article-title":"What do prostate cancer patients die of?","volume":"1","author":"Hemminki","year":"2011","journal-title":"Oncologist"},{"key":"17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1557988318798279","article-title":"Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location","volume":"1","author":"Taitt","year":"2018","journal-title":"Am J Mens Health"},{"key":"18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"1","author":"Korbonits","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"10","author":"Moller","year":"2001","journal-title":"J Clin Invest"},{"key":"20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10059-013-0169-8","article-title":"Metabolic roles of AMPK and metformin in cancer cells","volume":"3","author":"Park","year":"2013","journal-title":"Mol Cells"},{"key":"21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"3","author":"Shaw","year":"2008","journal-title":"Mol Cell"},{"key":"22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"32","author":"Thompson","year":"2009","journal-title":"Science"},{"key":"23","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1242\/jcs.02648","article-title":"The insulin-PI3K\/TOR pathway induces a HIF-dependent transcriptional response in Drosophila by promoting nuclear localization of HIF-alpha\/Sima","volume":"11","author":"Wappner","year":"2005","journal-title":"J Cell Sci"},{"key":"24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12935-021-02043-2","article-title":"Metformin exerts anti-AR-negative prostate cancer activity via AMPK\/autophagy signaling pathway","volume":"2","author":"Hou","year":"2021","journal-title":"Cancer Cell Int"},{"key":"25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Picus","year":"2015","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"publisher","first-page":"vi244","DOI":"10.1093\/annonc\/mdw372.04","article-title":"Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone na\u00efve metastatic prostate cancer (PrCa): E3805 CHAARTED trial","volume":"2","author":"Vogelzang","year":"2016","journal-title":"Annals of Oncology"},{"key":"27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"38","author":"Jones","year":"2016","journal-title":"Lancet"},{"key":"28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial","volume":"7","author":"Deplanque","year":"2016","journal-title":"Eur Urol"},{"key":"29","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.urolonc.2013.08.011","article-title":"Commentary on \u201cAndrogen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.\u201d Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France","volume":"3","author":"Trump","year":"2013","journal-title":"Lancet Oncol 2013; 14:149-58 [Epub 2013 Jan 8]. Urol Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40262-015-0323-x","article-title":"Therapeutic Concentrations of Metformin: A Systematic Review","volume":"5","author":"Lalau","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"31","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.juro.2014.12.086","article-title":"The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy","volume":"19","author":"Planas","year":"2015","journal-title":"J Urol"},{"key":"32","doi-asserted-by":"publisher","first-page":"E300","DOI":"10.5489\/cuaj.3655","article-title":"Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy","volume":"1","author":"Kerigh","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jdi.12075","article-title":"Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness","volume":"4","author":"Son","year":"2013","journal-title":"J Diabetes Investig"},{"key":"34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1559-4572.2008.00044.x","article-title":"The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus","volume":"4","author":"MacCallum","year":"2009","journal-title":"J Cardiometab Syndr"},{"key":"35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2164\/jandrol.108.005454","article-title":"Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth","volume":"2","author":"Basaria","year":"2008","journal-title":"J Androl"},{"key":"36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11934-008-0035-y","article-title":"Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors","volume":"9","author":"Smith","year":"2008","journal-title":"Curr Urol Rep"},{"key":"37","doi-asserted-by":"publisher","first-page":"6S28","DOI":"10.1016\/s1262-3636(03)72785-2","article-title":"Reducing insulin resistance with metformin: the evidence today","volume":"2","author":"Del Prato","year":"2003","journal-title":"Diabetes Metab"},{"key":"38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","article-title":"The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial","volume":"14","author":"Fowler","year":"2005","journal-title":"Ann Intern Med"},{"key":"39","first-page":"441","article-title":"Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus","volume":"5","author":"Masoodi","year":"2005","journal-title":"J Assoc Physicians India"},{"key":"40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2337\/dc11-1465","article-title":"Quantifying the effect of metformin treatment and dose on glycemic control","volume":"3","author":"Stevens","year":"2012","journal-title":"Diabetes Care"},{"key":"41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"2","author":"Turner","year":"1985","journal-title":"Diabetologia"},{"key":"42","doi-asserted-by":"publisher","first-page":"E1269","DOI":"10.1152\/ajpendo.90207.2008","article-title":"Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats","volume":"29","author":"Ramos","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clinbiochem.2014.02.007","article-title":"Age- and sex-specific reference values for fasting serum insulin levels and insulin resistance\/sensitivity indices in healthy Iranian adults: Tehran Lipid and Glucose Study","volume":"4","author":"Azizi","year":"2014","journal-title":"Clin Biochem"},{"key":"44","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","article-title":"A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy","volume":"10","author":"Laing","year":"2012","journal-title":"BJU Int"},{"key":"45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrclinonc.2013.169","article-title":"Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates","volume":"1","author":"Rennert","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"46","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"33","author":"Morris","year":"2005","journal-title":"BMJ"},{"key":"47","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3892\/ol.2022.13325","article-title":"Metformin: A promising drug for human cancers","volume":"2","author":"Huang","year":"2022","journal-title":"Oncol Lett"},{"key":"48","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/aje\/kwn190","article-title":"Antidiabetic medication and prostate cancer risk: a population-based case-control study","volume":"16","author":"Auvinen","year":"2008","journal-title":"Am J Epidemiol"},{"key":"49","doi-asserted-by":"publisher","first-page":"27692","DOI":"10.1074\/jbc.M114.592576","article-title":"Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors","volume":"28","author":"Safe","year":"2014","journal-title":"J Biol Chem"},{"key":"50","doi-asserted-by":"publisher","first-page":"14404","DOI":"10.1038\/srep14404","article-title":"Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK\/P70S6K Signaling","volume":"5","author":"Gou","year":"2015","journal-title":"Sci Rep"},{"key":"51","doi-asserted-by":"publisher","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"6","author":"Pollak","year":"2006","journal-title":"Cancer Res"},{"key":"52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11934-017-0693-8","article-title":"Metformin and Prostate Cancer: a New Role for an Old Drug","volume":"1","author":"Sooriakumaran","year":"2017","journal-title":"Curr Urol Rep"},{"key":"53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/jamaoncol.2021.7015","article-title":"Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial","volume":"8","author":"Rosell","year":"2022","journal-title":"JAMA Oncol"},{"key":"54","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.radonc.2016.01.012","article-title":"Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy","volume":"11","author":"Troost","year":"2016","journal-title":"Radiother Oncol"},{"key":"55","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1158\/2159-8290.CD-11-0280","article-title":"Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A","volume":"2","author":"Marais","year":"2012","journal-title":"Cancer Discov"},{"key":"56","doi-asserted-by":"publisher","first-page":"8540","DOI":"10.3390\/ijms21228540","article-title":"Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review","volume":"2","author":"Koo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"57","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.numecd.2015.03.007","article-title":"Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes","volume":"2","author":"Avogaro","year":"2015","journal-title":"A randomized controlled trial. Nutr Metab Cardiovasc Dis"},{"key":"58","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.eururo.2013.12.057","article-title":"Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08\/09)","volume":"6","author":"Gillessen","year":"2014","journal-title":"Eur Urol"},{"key":"59","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/dmd.115.067223","article-title":"Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects","volume":"4","author":"Shu","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"60","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"10","author":"Dobs","year":"2006","journal-title":"Cancer"},{"key":"61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/cancers14010069","article-title":"Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study","volume":"1","author":"de Braud","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T12:33:57Z","timestamp":1687178037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,6,19]]}},"alternative-id":["28458"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28458","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]}}}